VIVO CAPITAL LLC
Q2 2026 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001674712
· CRD 159868
· SEC-registered investment adviser
$1.1B Reported Value Total
VIVO CAPITAL, LLC reports 16 total accounts under management (AUM). There are 16 discretionary accounts valued at $6,095,582,206, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
29 funds
· $7.5B gross asset value
Private Equity Fund: $4.4B · Other: $2.2B · Venture Capital Fund: $899.0M · Securitized Asset Fund: $49.8M
Source: Form ADV filed 2026-03-31
Reported value
$1.1B
Quarter over quarter
+8.3%
Holdings
47
Top-10 concentration
52.4%
Key People
Form ADV owners & control persons
Frank Fang-Chien Kung
MANAGING PARTNER
Edgar George Engleman
MANAGING PARTNER
Shan (nmn) Fu
MANAGING PARTNER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $1.1B |
| Positions | 47 |
| Change in reported value | -9.0% |
| New positions | 7 |
| Exited positions | 6 |
| Position turnover | 24.5% |
| Top-10 concentration | 52.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
47 | $1.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
46 | $1.2B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
47 | $1.5B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
47 | $1.2B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
42 | $977.1M |
|
Q1 2025 13F
Filed May 12, 2025
|
40 | $755.1M |
|
Q4 2024 13F
Filed Feb 13, 2025
|
40 | $892.6M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
43 | $1.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
42 | $1.1B |
|
Q1 2024 13F
Filed Apr 22, 2024
|
42 | $1.3B |
|
Q4 2023 13F
Filed Feb 7, 2024
|
47 | $1.2B |
|
Q3 2023 13F
Filed Nov 8, 2023
|
53 | $912.8M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
48 | $1.4B |
|
Q1 2023 13F
Filed May 15, 2023
|
48 | $1.4B |
|
Q4 2022 13F
Filed Feb 13, 2023
|
48 | $868.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
51 | $905.8M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
49 | $995.9M |
|
Q1 2022 13F
Filed May 13, 2022
|
54 | $1.5B |
|
Q4 2021 13F
Filed Feb 11, 2022
|
55 | $1.7B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
60 | $2.2B |
22 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | TRVI Trevi Therapeutics Inc | $95.0M | 8.68% |
| 2 | PRAX Praxis Precision Medicines | $90.8M | 8.29% |
| 3 | ERAS Erasca Inc | $75.6M | 6.9% |
| 4 | AVBP Arrivent BioPharma Inc | $58.4M | 5.34% |
| 5 | ABVX Abivax SA - ADR | $55.3M | 5.05% |
| 6 | TNGX Tango Therapeutics Inc | $43.1M | 3.94% |
| 7 | CRVS Corvus Pharmaceuticals Inc | $41.9M | 3.83% |
| 8 | DRUG Bright Minds Biosciences Inc | $39.1M | 3.57% |
| 9 | SVA Sinovac Biotech Ltd. | $38.2M | 3.49% |
| 10 | TENX Tenax Therapeutics Inc | $36.4M | 3.32% |
| 11 | ACRS Aclaris Therapeutics, Inc. | $35.4M | 3.23% |
| 12 | DYN Dyne Therapeutics Inc | $34.6M | 3.16% |
| 13 | DNTH Dianthus Therapeutics Inc | $34.5M | 3.15% |
| 14 | ANRO Alto Neuroscience Inc | $31.9M | 2.91% |
| 15 | DBVT DBV Technologies SA | $30.3M | 2.76% |
| 16 | SABS SAB Biotherapeutics Inc | $28.5M | 2.6% |
| 17 | MLTX Moonlake Immunotherapeutics | $27.3M | 2.49% |
| 18 | LBRX LB Pharmaceuticals Inc | $26.0M | 2.37% |
| 19 | NERV Minerva Neurosciences Inc | $24.0M | 2.19% |
| 20 | DSGN Design Therapeutics Inc | $23.3M | 2.13% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.